| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 77131 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
95 |
zyl |
2024-12-19 |
| 77132 |
MC-Sq-Cit-PAB-Dolastatin10 ，cas:1941168-65-5，ADC定制 |
108 |
wyh |
2024-12-19 |
| 77133 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
101 |
zyl |
2024-12-19 |
| 77134 |
N3-PEG4-DYKDDDD-Doxorubicin，ADC定制 |
113 |
wyh |
2024-12-19 |
| 77135 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
76 |
zyl |
2024-12-19 |
| 77136 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
100 |
zyl |
2024-12-19 |
| 77137 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
101 |
zyl |
2024-12-19 |
| 77138 |
MC-GGFG-DX8951 cas:1600418-29-8 |
84 |
zyl |
2024-12-19 |
| 77139 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
109 |
h |
2024-12-19 |
| 77140 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
209 |
zyl |
2024-12-19 |
| 77141 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
111 |
h |
2024-12-19 |
| 77142 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
132 |
h |
2024-12-19 |
| 77143 |
VC-SECO DUBA analogue，ADC定制 |
103 |
wyh |
2024-12-19 |
| 77144 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
101 |
h |
2024-12-19 |
| 77145 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
164 |
h |
2024-12-19 |
| 77146 |
Vc-MMAD cas:1401963-17-4的结构式 |
84 |
zyl |
2024-12-19 |
| 77147 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
109 |
h |
2024-12-19 |
| 77148 |
CL2A-SN38，cas:1279680-68-0，ADC定制 |
187 |
wyh |
2024-12-19 |
| 77149 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
91 |
h |
2024-12-19 |
| 77150 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
167 |
h |
2024-12-19 |
| 77151 |
MC-MMAF ， cas:863971-19-1，ADC定制 |
122 |
wyh |
2024-12-19 |
| 77152 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
151 |
zyl |
2024-12-19 |
| 77153 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
104 |
h |
2024-12-19 |
| 77154 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
111 |
h |
2024-12-19 |
| 77155 |
Vc-MMAE， cas:646502-53-6，ADC定制 |
151 |
wyh |
2024-12-19 |
| 77156 |
Azido-PEG4-MMAE |
124 |
zyl |
2024-12-19 |
| 77157 |
cas:2055024-59-2，Fmoc-PEG2-Val-Cit-PAB-OH |
123 |
zyl |
2024-12-19 |
| 77158 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin，ADC定制 |
125 |
wyh |
2024-12-19 |
| 77159 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
80 |
h |
2024-12-19 |
| 77160 |
cas:1807530-16-0，2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
104 |
zyl |
2024-12-19 |
| 77161 |
DOTA偶联受体特异性肽 |
130 |
h |
2024-12-19 |
| 77162 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
115 |
h |
2024-12-19 |
| 77163 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
119 |
h |
2024-12-19 |
| 77164 |
ALD-tetra-EG-Osu的介绍 |
139 |
zyl |
2024-12-19 |
| 77165 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
245 |
h |
2024-12-19 |
| 77166 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
107 |
h |
2024-12-19 |
| 77167 |
cas:55750-63-5，Mal-heptanoic NHS ester |
130 |
zyl |
2024-12-19 |
| 77168 |
DOTA-Fab-PEG24-EGF DOTA-PEG修饰曲妥珠单抗Fab片段偶联表皮生长因子 |
115 |
h |
2024-12-19 |
| 77169 |
cas:663599-10-8，DMAC-SPP |
116 |
zyl |
2024-12-19 |
| 77170 |
多甲基化的1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体 |
156 |
h |
2024-12-19 |
| 77171 |
PEG-pGlu(DOTA)8-LA4 |
64 |
h |
2024-12-19 |
| 77172 |
cas:937025-17-7，2,5-Dioxopyrrolidin-1-yl 2-oxo-6,9,12,15-tetraoxa-3-thiaoctadecan-18-oate |
154 |
zyl |
2024-12-19 |
| 77173 |
DOTA-Hyd-TRP PET示踪剂 |
119 |
h |
2024-12-19 |
| 77174 |
Ga-DOTATOC Ga-DOTA-D-Phe-Tyr-奥曲肽 |
167 |
h |
2024-12-19 |
| 77175 |
cas:1226371-65-8，N-(2-(2,5-Dimethylphenoxy)ethyl)-4-formylbenzamide |
91 |
zyl |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询